Amneal Ready To Go Head-To-Head With Mylan’s Xulane In US
Gains 180 Days Of CGT Exclusivity For Generic Of Ortho Evra Contraceptive Patch
Amneal is set to benefit from 180 days of US exclusivity for its norelgestromin and ethinyl estradiol contraceptive patch product after receiving FDA approval with a competitive generic therapy designation. The generic will be the only competitor to Mylan’s Xulane version.
